Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Biotechnology companies broaden antisense drug development partnership
April 14th, 2005
OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc., (ISIS) announced that they have broadened their antisense drug development partnership to allow for the development of two additional second-generation antisense anticancer drug candidates. OncoGenex and Isis initiated a partnership in December 2001 to codevelop OGX-011, a drug currently in phase 1/2 development for the treatment of prostate, breast and lung cancers. In 2003, OncoGenex and Isis added a second drug to their collaboration, OGX-225, which is in the research phase of development. OncoGenex has not yet selected the molecular targets for drug development under this new agreement. Specific financial...
Source: Women's Health Weekly (2005-04-14)
|
